Dario Expands Contract with a Leading Regional Grocery Retailer, Adding Women's Digital Health and Clinical Care Program
The expanded program will extend an existing cardiometabolic client relationship into perimenopause and menopause support.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DarioHealth (DRIO) expanded its contract with a regional grocery retailer to add Dario Women, its perimenopause and menopause support program. The expanded program will be offered to eligible insured employees in January 2027. The retailer has used Dario's cardiometabolic solution since the beginning of 2025 and selected the additional program following employee demand and an evaluation with its benefits consultant.
Dario Women launched in August 2026, combining behavioral coaching and access to licensed healthcare providers, with optional evaluation for hormone replacement therapy when medically appropriate. Dario said nearly 45% of its current book of business comprises women over age 40 who could potentially benefit, providing an opportunity to expand the program among existing clients. The company describes adding services to existing contracts as a way to increase revenue per customer with little incremental customer acquisition investment.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Contract expansion adds Dario Women for eligible insured retailer employees in January 2027.
- Minor pointNearly 45% of the current book of business comprises women over 40 who could potentially benefit.
Negative
- None.
Details
Market Reaction – DRIO
On Oct 26, the day this news came out, the latest delayed price for DRIO is 1.47% below the previous close. Our momentum scanner has recorded 17 alerts for this stock so far that day. The latest delayed price is $3.35. Relative volume is exceptionally heavy at 5.4x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Program availability
- January 2027
- Expanded program offered to eligible insured employees
- Women over age 40
- Nearly 45%
- Share of Dario's current book of business
- Higher healthcare spending
- 46% higher
- Spending among women in perimenopause/menopause, as stated in the article
Historical Context
-
Launched Dario Women and outlined anticipated client rollout and recurring revenue timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
annual recurring revenue financial
hormone replacement therapy medical
cardiometabolic medical
perimenopause medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Contract extension follows benefits realized from Dario's cardiometabolic program and strong employee demand for perimenopause support
Nearly
Dario's expanding multi-condition platform addresses a larger share of clients' membership bases, delivering greater value to payers while increasing the Company's annual recurring revenue base
The client, a leading regional grocery retailer with over 200 stores and more than 19,000 employees, has used Dario's cardiometabolic solution since the beginning of 2025. Based on employee demand, the client was actively seeking a Women's Health solution in the market and selected Dario's newly-launched program after evaluation in collaboration with their benefit consultant. In addition to expanding the relationship, this extension allows Dario's multi-condition platform to accelerate favorable cardiometabolic health outcomes and associated downstream cost savings.
Dario Women launched in August 2026 as an extension of Dario's provider-backed cardiometabolic platform, as women in perimenopause/menopause are among the highest-cost members in any employer population, with
"This client's decision to expand its program demonstrates two important parts of our growth strategy: our cardiometabolic platform is delivering value that helps us retain and expand with existing clients, and we are successfully adding new solutions that mirror the health requirements of our clients' evolving populations, addressing a larger share of their insured members," said Erez Raphael, Chief Executive Officer of Dario. "Demand from the client's employees for perimenopause support also validates our decision to launch Dario Women. With nearly
The expansion provides further evidence of Dario's land-and-expand strategy, in which demonstrated results with existing clients create opportunities to add conditions and increase revenue per customer with little incremental customer acquisition investment.
About DarioHealth Corp.
DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.
Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected launch of the program with the client and the timing thereof; the ability of the contract expansion with the client to expand the reach of the Company's Dario Woman program; the ability of the contract extension to accelerate favorable cardiometabolic health outcomes and associated downstream cost savings; and the scalability, growth potential and expected benefits of the Company's "land-and-expand" strategy and capabilities of the Dario Women program. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contacts
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310
Rob Halpern
SVP Marketing
irteam@dariohealth.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/dario-expands-contract-with-a-leading-regional-grocery-retailer-adding-womens-digital-health-and-clinical-care-program-302917540.html
SOURCE DarioHealth Corp.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will DarioHealth's expanded grocery retailer program become available?
The retailer will offer Dario Women to eligible insured employees in January 2027. The expansion adds perimenopause and menopause support to a client relationship that has included Dario's cardiometabolic solution since the beginning of 2025.